MedTrace Logo

Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score

NCT07687758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 571

Last updated 2026-07-07

No results posted yet for this study

Summary

This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who achieved sustained virological response after sofosbuvir-based direct-acting antiviral therapy. Patients treated at Siriraj Hospital between 2013 and 2023 were included if they had compensated advanced chronic liver disease and documented SVR12. The study compared FIB-4, APRI, ALBI, and aMAP scores calculated at SVR12 for prediction of hepatocellular carcinoma during long-term follow-up. The primary aim was to identify a very-low-risk subgroup in whom hepatocellular carcinoma surveillance might potentially be de-escalated.

Conditions

  • Hepatitis C Virus Infection
  • Compensated Advanced Chronic Liver Disease
  • Hepatocellular Carcinoma (HCC)

Interventions

OTHER

Non-invasive Risk Score Assessment

FIB-4, APRI, ALBI, and aMAP scores were calculated using laboratory values at SVR12 to evaluate their performance for predicting de novo hepatocellular carcinoma during follow-up.

Sponsors & Collaborators

  • Siriraj Hospital

    lead OTHER

Principal Investigators

  • Tawesak Tanwandee, MD · Siriraj Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07687758 on ClinicalTrials.gov